You are here

Prism II Clinical Trials

PRISM IIPRISM II is a real-world registry to study the safety and effectiveness of NUEDEXTA in the treatment of pseudobulbar affect (PBA) in post-stroke, dementia and traumatic brain injury (TBI) patients.

Pseudobulbar affect is a neurologic condition that can occur when certain neurologic diseases or brain injuries damage the areas of the brain that control normal expression of emotion. The condition of pseudobulbar affect (PBA) results in episodes of crying or laughing that are often sudden and exaggerated or do not match what the person is feeling inside.

Nearly 2 million Americans with certain neurologic conditions or brain injuries are estimated to suffer from PBA. PBA can affect men and women, old and young.

PRISM II is a 12-week long study testing the safety and effectiveness of NUEDEXTA in the treatment of PBA in post-stroke, dementia and traumatic brain injury (TBI) patients.

NUEDEXTA is an FDA-approved treatment for PBA. NUEDEXTA is a combination of two drugs, dextromethorphan and quinidine.

During the three-month duration of the study, participants will be asked to visit the investigator site three times for safety and effectiveness measures and study-related examinations.

  • There are no costs to participate.
  • Participants will receive study-related medical care at no cost.
  • Participants will receive study medication at no cost.

How to Participate in PRISM II

Participation in the study is only possible if you visit one of the qualified investigation sites. Your eligibility to participate in the study will be assessed upon your contacting or visiting the investigation site. This decision can only be made by the physicians who have been trained for the study.

To learn more about this study or to find out if a qualified study site is reachable for you (or your patients), please go to www.avanirclinicaltrials.com/prism-II or call 1 (855) 477-4762.

NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20mg/10mg capsules can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. Please see the important safety information and full prescribing information.

The content of this webpage does not imply National Stroke Association's endorsement of any product, treatment, service or entity. National Stroke Association strongly recommends that you consult with a healthcare professional about diagnosis and treatment before participating in a clinical trial. National Stroke Association has no affiliation with any specific clinical trials.         

Additional Resources

Find a Support Group

Go

 

Learn more about spasticity - a common post-stroke condition

Seeking more information about spasticity? The Spasticity Alliance is here to help.

Learn more

Get Involved

 

For over 30 years we have been the trusted source for free resources and education to the stroke community. Together, we empower survivors and their circle of care to thrive after stroke. Make your tax-deductible donation today to support the growing needs of the stroke community.